JP2022510218A5 - - Google Patents
Info
- Publication number
- JP2022510218A5 JP2022510218A5 JP2021530200A JP2021530200A JP2022510218A5 JP 2022510218 A5 JP2022510218 A5 JP 2022510218A5 JP 2021530200 A JP2021530200 A JP 2021530200A JP 2021530200 A JP2021530200 A JP 2021530200A JP 2022510218 A5 JP2022510218 A5 JP 2022510218A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- sequence numbers
- sequence
- immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024133895A JP2024174865A (ja) | 2018-11-30 | 2024-08-09 | ヘテロ二量体四価特異性抗体およびこれらの使用 |
| JP2026042273A JP2026116944A (ja) | 2018-11-30 | 2026-03-16 | ヘテロ二量体四価特異性抗体およびこれらの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862774111P | 2018-11-30 | 2018-11-30 | |
| US62/774,111 | 2018-11-30 | ||
| US201962794523P | 2019-01-18 | 2019-01-18 | |
| US62/794,523 | 2019-01-18 | ||
| PCT/US2019/063854 WO2020113164A1 (en) | 2018-11-30 | 2019-11-29 | Heterodimeric tetravalency and specificity antibody compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024133895A Division JP2024174865A (ja) | 2018-11-30 | 2024-08-09 | ヘテロ二量体四価特異性抗体およびこれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022510218A JP2022510218A (ja) | 2022-01-26 |
| JP2022510218A5 true JP2022510218A5 (enExample) | 2022-12-05 |
Family
ID=70853677
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530200A Pending JP2022510218A (ja) | 2018-11-30 | 2019-11-29 | ヘテロ二量体四価特異性抗体およびこれらの使用 |
| JP2024133895A Pending JP2024174865A (ja) | 2018-11-30 | 2024-08-09 | ヘテロ二量体四価特異性抗体およびこれらの使用 |
| JP2026042273A Pending JP2026116944A (ja) | 2018-11-30 | 2026-03-16 | ヘテロ二量体四価特異性抗体およびこれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024133895A Pending JP2024174865A (ja) | 2018-11-30 | 2024-08-09 | ヘテロ二量体四価特異性抗体およびこれらの使用 |
| JP2026042273A Pending JP2026116944A (ja) | 2018-11-30 | 2026-03-16 | ヘテロ二量体四価特異性抗体およびこれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220098329A1 (enExample) |
| EP (1) | EP3902834A4 (enExample) |
| JP (3) | JP2022510218A (enExample) |
| AU (1) | AU2019387482A1 (enExample) |
| CA (1) | CA3121168A1 (enExample) |
| WO (1) | WO2020113164A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| AU2020392243A1 (en) | 2019-11-28 | 2022-06-16 | Regenxbio Inc. | Microdystrophin gene therapy constructs and uses thereof |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| WO2022018262A1 (en) | 2020-07-24 | 2022-01-27 | Cellectis S.A. | T-cells expressing immune cell engagers in allogenic settings |
| EP4192489A4 (en) | 2020-08-05 | 2024-12-11 | Synthekine, Inc. | IL2RB-BINDING MOLECULES AND METHODS OF USE |
| JP7743500B2 (ja) | 2020-08-05 | 2025-09-24 | シンセカイン インコーポレイテッド | Ｉｌ１０受容体結合性分子および使用方法 |
| US12540188B2 (en) | 2020-08-05 | 2026-02-03 | Synthekine, Inc. | IL10Rα/IL2Rγ synthetic cytokines |
| US11124568B1 (en) * | 2020-08-19 | 2021-09-21 | Vitruviae LLC | CD3/CD25 antibodies for neuro-immune diseases |
| EP4210832A1 (en) * | 2020-09-14 | 2023-07-19 | Vor Biopharma, Inc. | Chimeric antigen receptors for treatment of cancer |
| AU2021381768A1 (en) * | 2020-11-18 | 2023-06-22 | Memorial Sloan Kettering Cancer Center | Anti-gpa33 multi-specific antibodies and uses thereof |
| AU2022205313A1 (en) * | 2021-01-06 | 2023-07-20 | Tonix Pharma Limited | Methods of inducing immune tolerance with modified anti-cd154 antibodies |
| WO2022150791A2 (en) * | 2021-01-11 | 2022-07-14 | Synthekine, Inc. | Compositions and methods related to il2 receptor binding |
| AU2022218137A1 (en) | 2021-02-03 | 2023-08-24 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| EP4341300A1 (en) | 2021-05-21 | 2024-03-27 | Cellectis S.A. | Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| CN117940459A (zh) * | 2021-08-25 | 2024-04-26 | 西雅图免疫公司 | 靶向egfr和her3的双特异性四价抗体 |
| WO2023055376A1 (en) * | 2021-09-30 | 2023-04-06 | Virtuoso Binco, Inc. | Multispecific antibodies for targeting cd47 and icam1 and methods of use thereof |
| EP4419567A4 (en) * | 2021-10-20 | 2025-09-17 | Memorial Sloan Kettering Cancer Center | MULTI-SPECIFIC ANTI-TSHR ANTIBODIES AND THEIR USES |
| JP2024540374A (ja) | 2021-11-05 | 2024-10-31 | アメリカン ダイアグノスティックス アンド セラピー， エルエルシー （エーディーエックスアールエックス） | がん胎児性抗原に対するモノクローナル抗体、及びそれらの使用 |
| JP7767613B2 (ja) | 2021-11-15 | 2025-11-11 | システィミューン，インコーポレイテッド | 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用 |
| EP4467569A4 (en) * | 2022-01-21 | 2026-02-11 | Harbour Biomed Shanghai Co Ltd | ANTI-B7-H7 ANTIBODIES OR ANTIGEN-BINDING FRAGMENT OF THESE, ITS PREPARATION PROCESS AND ITS USE |
| IL315960A (en) | 2022-03-30 | 2024-11-01 | Pinetree Therapeutics Inc | Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof |
| CN114685609B (zh) * | 2022-04-11 | 2023-04-14 | 东北农业大学 | 一种超短自组装抗菌肽fwr及其制备方法与应用 |
| US20250002588A1 (en) | 2023-04-07 | 2025-01-02 | Diagonal Therapeutics Inc. | Bispecific agonistic antibodies to activin a receptor like type 1 (alk1) |
| EP4720125A1 (en) | 2023-05-30 | 2026-04-08 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| EP4762093A1 (en) | 2023-08-14 | 2026-06-24 | Paragon Therapeutics, Inc. | Alpha 4 beta 7 integrin binding proteins and methods of use |
| CN118146376B (zh) * | 2024-05-09 | 2024-07-05 | 成都微芯新域生物技术有限公司 | Hla-g抗体及其制备方法和用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US7070995B2 (en) * | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US7125843B2 (en) * | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
| WO2009129538A2 (en) * | 2008-04-18 | 2009-10-22 | Xencor, Inc. | Human equivalent monoclonal antibodies engineered from nonhuman variable regions |
| NZ603581A (en) * | 2010-06-19 | 2015-05-29 | Sloan Kettering Inst Cancer | Anti-gd2 antibodies |
| CN103429620B (zh) * | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| WO2012162067A2 (en) * | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
| KR101850591B1 (ko) * | 2012-10-05 | 2018-04-19 | 제넨테크, 인크. | 염증성 장 질환의 진단 및 치료 방법 |
| SG11201506451UA (en) * | 2013-03-06 | 2015-09-29 | Merrimack Pharmaceuticals Inc | Anti-c-met tandem fc bispecific antibodies |
| MX2015013163A (es) * | 2013-03-15 | 2016-04-04 | Zyngenia Inc | Complejos multiespecificos multivalente y monovalentes y sus usos. |
| CN105530959B (zh) * | 2013-03-15 | 2021-09-17 | 纪念斯隆-凯特琳癌症中心 | 多聚化技术 |
| CA2904805A1 (en) * | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| ES2959480T3 (es) * | 2014-02-07 | 2024-02-26 | Univ Mcmaster | Acoplador de células T - antígeno trifuncional y métodos y usos del mismo |
| MX386342B (es) * | 2014-07-25 | 2025-03-18 | Memorial Sloan Kettering Cancer Center | Móleculas de unión a her2 y cd3 biespecíficas. |
| BR112017024770A2 (pt) * | 2015-05-21 | 2018-07-31 | Alligator Bioscience Ab | polipeptídeos inovadores |
| EP3526257A2 (en) * | 2016-10-14 | 2019-08-21 | Dana-Farber Cancer Institute, Inc. | Modular tetravalent bispecific antibody platform |
| EP3574012A1 (en) * | 2017-01-27 | 2019-12-04 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
| KR20190140943A (ko) * | 2017-04-24 | 2019-12-20 | 메모리얼 슬로안 케터링 캔서 센터 | 항-cd33 항체 제제 |
-
2019
- 2019-11-29 JP JP2021530200A patent/JP2022510218A/ja active Pending
- 2019-11-29 CA CA3121168A patent/CA3121168A1/en active Pending
- 2019-11-29 WO PCT/US2019/063854 patent/WO2020113164A1/en not_active Ceased
- 2019-11-29 EP EP19889678.9A patent/EP3902834A4/en active Pending
- 2019-11-29 US US17/298,008 patent/US20220098329A1/en active Pending
- 2019-11-29 AU AU2019387482A patent/AU2019387482A1/en active Pending
-
2024
- 2024-08-09 JP JP2024133895A patent/JP2024174865A/ja active Pending
-
2026
- 2026-03-16 JP JP2026042273A patent/JP2026116944A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Labrijn et al. | Bispecific antibodies: a mechanistic review of the pipeline | |
| Surowka et al. | Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins | |
| Sedykh et al. | Bispecific antibodies: design, therapy, perspectives | |
| US12448423B2 (en) | Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains | |
| TWI828625B (zh) | 引導及導航控制蛋白質以及彼之製造及使用方法 | |
| US20240010748A1 (en) | Bispecific antibody for claudin 18a2 and cd3 and application of bispecific antibody | |
| US20230340130A1 (en) | Multi-specific binding proteins for cancer treatment | |
| JP2024174865A (ja) | ヘテロ二量体四価特異性抗体およびこれらの使用 | |
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP2023503943A (ja) | がんを治療するための組み合わせ療法 | |
| CN117285642A (zh) | 制导和导航控制蛋白及其制备和使用方法 | |
| WO2023056312A1 (en) | Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof | |
| Golay et al. | Design and validation of a novel generic platform for the production of tetravalent IgG1-like bispecific antibodies | |
| JP2025069123A (ja) | ガイダンス及びナビゲーションコントロール（ｇｎｃ）抗体様タンパク質、その製造方法及び使用方法 | |
| Guo et al. | Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment | |
| CN113490690A (zh) | 异源二聚体融合蛋白 | |
| US20230002488A1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| Fine et al. | Mechanism-driven design of multispecific antibodies for targeted disease treatment | |
| EP4469478A1 (en) | Bispecific molecule with tunable affinity to a targetted antigen | |
| Li et al. | Highlights of 2019 protein engineering summit (PEGS) in Boston, USA: advancing antibody-based cancer therapies to the clinic | |
| Li et al. | Advancing immunotherapy via multiple immune cells co-engagement | |
| Way et al. | Bioinspired design of artificial signaling systems | |
| JP2024513485A5 (enExample) | ||
| CN116874606B (zh) | 一种靶向trop2和cd3的双特异性抗体及其制备方法与应用 | |
| Wozniak-Knopp | Bispecific antibodies |